UNC Landmark Study Empowers Nurse Midwives to Perform at Level of Trained Sonographers Using Butterfly

Unique scanning method coupled with artificial intelligence, paves the way for universal obstetric ultrasound

GUILFORD, Conn. & NEW YORK--(BUSINESS WIRE)-- Butterfly Network, Inc. (NYSE: BFLY), (the company) a digital health company transforming care with handheld, whole-body ultrasound, today announced its position in a new study published in NEJM Evidence, which introduces a significant opportunity to democratize obstetric ultrasound.

The study, conducted from September 2018 through June 2021, recruited 4,695 pregnant volunteers in North Carolina and Zambia. The volunteers received blind ultrasound sweeps of the pregnant abdomen alongside standard fetal measurements, collected on both the commercial ultrasound machine and on Butterfly iQ, the company’s handheld, whole-body point-of-care ultrasound probe. Researchers trained a neural network to estimate gestational age from the sweeps.

Joni Price, MD, an assistant professor of obstetrics and gynecology at UNC who lives full time in Zambia and led study implementation recognizes the disruptive potential of Butterfly. “Armed with a pocket-sized Butterfly probe and a smartphone, a Zambian midwife with no prior training in sonography can assess gestational age as accurately as a certified sonographer using an expensive machine. This has the potential to revolutionize the delivery of obstetric care in settings like Zambia.”

Establishing accurate gestational age with ultrasound early in pregnancy is essential to delivering high-quality care. Yet, the high cost for equipment and the need for trained sonographers limits its use in low-resource settings.

Jeff Stringer, MD, associate director of UNC’s Institute for Global Health and Infectious Diseases came up with the idea for this project. “Ultrasound is like a stethoscope to the modern obstetrician. We use it all day, every day. These results foretell a future where all pregnant people – not just those who live in rich countries – can access the diagnostic benefits of obstetric ultrasound.” Dr. Stringer directs UNC’s Division of Global Women’s Health and is a professor of obstetrics and gynecology.

“Prior to this important research, access to low-cost imaging devices and the expertise to perform scans presented challenging hurdles to overcome in low-resource care settings,” said Dr. John Martin, Chief Medical Officer, Butterfly Network. “The results of this study offer hope to millions of mothers when it comes to determining risk and sequencing care. The findings also reinforce our belief that mid-level practitioners, when armed with the right tools, can meaningfully improve outcomes and advance the standard of care.”

Funded by the Bill and Melinda Gates Foundation, this research is part of the Fetal Age Machine Learning Initiative (FAMLI), an ongoing project that is developing technologies to expand obstetrical ultrasound access to low-income settings where cost and logistics have traditionally prevented its use.

Separate from this study, and through the support of a grant from the Bill & Melinda Gates Foundation, Butterfly recently announced that it will distribute 1,000 Butterfly iQ+ devices to healthcare workers in Sub-Saharan Africa, in part, to advance maternal and fetal health.

To read the full study, “AI Estimation of Gestational Age from Blind Ultrasound Sweeps in Low-Resource Settings,” please visit NEJM Evidence.

To learn more about the impact of Butterfly technology and to view a demo of Butterfly iQ+, visit: https://www.butterflynetwork.com.

About Butterfly Network

Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased online today by healthcare practitioners in the United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.

Butterfly iQ+ is a prescription device intended for trained healthcare professionals only.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to financial results, future performance, development of products and services, and the size and potential growth of current or future markets for its products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business, including issues relating to Omicron or other variants; the ability to recognize the anticipated benefits of the business combination; the Company’s ability to grow and manage growth profitably; the success, cost and timing of the Company’s product and service development activities; the potential attributes and benefits of the Company’s products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture, supply and distribution agreements; manufacturing and supply of the Company’s products; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using its products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s ability to raise financing in the future; and other risks and uncertainties indicated from time to time in the Company’s most recent Annual Report on Form 10-K or in subsequent filings that it makes with the Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. The Company does not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005043/en/

Butterfly Network:



Media

Holly Spring

781.888.8219

hspring@butterflynetwork.com



Investors

Agnes Lee

650.677.9138

alee@butterflynetwork.com

Source: Butterfly Network, Inc.